Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study used NMR spectroscopy and other techniques to fully assign the proton and 13C spectra of the 5α-reductase inhibitor finasteride.

This case report describes a unique presentation of frontal fibrosing alopecia characterized by a hair loss pattern that resembles the Greek letter upsilon, supported by trichoscopic and histological findings.

This study used fibre optic confocal imaging to visualize subsurface structures in live mouse skin, revealing cellular details and blood vessel networks that dynamic events could be studied in vivo.

This study found that certain circulating miRNAs in skin and plasma may serve as potential biomarkers for distinguishing frontal fibrosing alopecia from control cases, highlighting the need for further validation in larger cohorts.

In a pilot study with 21 patients, the niostem device increased hair counts and density and enhanced testers’ self-perception of hair growth at 6 months without reported adverse effects, suggesting potential benefits for androgenetic alopecia.

The researchers reported that nicotinic acid normalized excessive sebaceous lipogenesis without affecting basal lipogenesis and suggested potential anti-acne benefits.

This study suggests that weekly oral finasteride may be a promising alternative to isotretinoin for treating nodulocystic acne, showing substantial improvements with lower incidence of sexual dysfunction.

This study found that a topical transethosomal system may enhance the skin penetration and deposition of naftifine compared to a marketed cream, potentially overcoming the stratum corneum barrier.

This dissertation demonstrates that FERONIA regulates essential plant functions such as RAC/ROP signaling, pollen tube reception, cell wall integrity, and sugar signaling as a cell surface receptor kinase.

This review discusses the various factors implicated in the etiology of frontal fibrosing alopecia and notes the need for effective treatments, reporting no new clinical findings.

In this case report, a 14-year-old male with alopecia areata subtotalis and nail involvement showed significant improvement after 9 months of treatment with oral tofacitinib, including complete hair regrowth and nail texture improvement, though further studies are needed to confirm these findings.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This article discusses the DOAJ, a comprehensive index of international open access journals, and emphasizes its role in providing free quality content online without presenting new research findings.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study reports that familial frontal fibrosing alopecia was diagnosed earlier in premenopausal women compared to postmenopausal women, though long-term outcomes remain uncertain without a definitive treatment.

This study reported that phytosome formulations of citrus flavonoids naringenin and naringin showed significantly increased oral bioavailability and plasma drug concentration in rabbits, suggesting that phytosome technology effectively addresses the pharmacokinetic limitations of these compounds.

This case report highlights that frontal fibrosing alopecia can occur in black patients and may resemble androgenetic alopecia, underscoring the importance of considering FFA when diagnosing frontotemporal alopecia in this population.

This study developed nanostructured lipid carriers for finasteride that demonstrated high encapsulation efficiency and reduced cytotoxicity, suggesting potential as a topical treatment for androgenetic alopecia.

This study identifies NFAT5 as a crucial transcription factor necessary for triggering innate immune responses in the blood vessel lining that lead to atherosclerosis under hypertonic stress conditions.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This study demonstrated that Forsythiaside A protected against oxidative stress in both cell models and a mouse model of liver damage, suggesting its potential as a liver-protective agent.

This letter reports on a case of intractable ophiasis-type alopecia areata that was presumably improved by fexofenadine, but no new clinical results are presented.

In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.

In this case study, a young female with aseptic and alopecic nodules of the scalp achieved full resolution without recurrence using intralesional steroids.

This study in Morocco found that all women with frontal fibrosing alopecia presented frontotemporal hairline recession, with trichoscopic features such as perifollicular erythema and follicular hyperkeratosis being indicative of the condition, and suggested a potential link between cosmetic products or emotional factors and the disease.

Men with a certain type of hair loss often use facial moisturizers, and a specific antibiotic treatment may help another hair condition.

Frontal fibrosing alopecia may be caused by an autoimmune reaction and hormonal imbalance.

This study concluded that niosomes could effectively serve as stable carriers for topical aminexil delivery, showing promising stability and a slow, biphasic release profile in laboratory settings.

This study developed a personalized microneedle that delivers finasteride directly to the skin, facilitating a sustained release and potentially reducing side effects associated with oral administration.

In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.